MX382019B - Sal de un compuesto de pirimido [6,1-a]isoquinolin-4-ona. - Google Patents
Sal de un compuesto de pirimido [6,1-a]isoquinolin-4-ona.Info
- Publication number
- MX382019B MX382019B MX2017010195A MX2017010195A MX382019B MX 382019 B MX382019 B MX 382019B MX 2017010195 A MX2017010195 A MX 2017010195A MX 2017010195 A MX2017010195 A MX 2017010195A MX 382019 B MX382019 B MX 382019B
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- pyrimido
- isoquinolin
- salt
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502260A GB201502260D0 (en) | 2015-02-11 | 2015-02-11 | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| PCT/GB2016/050313 WO2016128742A1 (en) | 2015-02-11 | 2016-02-10 | Salt of a pyrimido[6,1-a]isoquinolin-4-one compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010195A MX2017010195A (es) | 2017-11-17 |
| MX382019B true MX382019B (es) | 2025-03-13 |
Family
ID=52781414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010195A MX382019B (es) | 2015-02-11 | 2016-02-10 | Sal de un compuesto de pirimido [6,1-a]isoquinolin-4-ona. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10463665B2 (enExample) |
| EP (2) | EP4461358A3 (enExample) |
| JP (2) | JP7089366B2 (enExample) |
| CN (2) | CN113105453A (enExample) |
| AU (2) | AU2016217674B2 (enExample) |
| CA (1) | CA2974605C (enExample) |
| ES (1) | ES3018557T3 (enExample) |
| GB (1) | GB201502260D0 (enExample) |
| IL (1) | IL253595B (enExample) |
| MX (1) | MX382019B (enExample) |
| PT (1) | PT3256472T (enExample) |
| WO (1) | WO2016128742A1 (enExample) |
| ZA (1) | ZA201705112B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| PT3332767T (pt) | 2014-09-15 | 2019-06-27 | Verona Pharma Plc | Formulação por inalação líquida compreendendo rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB201911517D0 (en) * | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| CA3167378A1 (en) * | 2020-01-15 | 2021-07-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound |
| WO2021213945A1 (en) * | 2020-04-22 | 2021-10-28 | Pfizer Inc. | Coronavirus vaccine |
| WO2023076205A1 (en) | 2021-10-29 | 2023-05-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of ensifentrine and process for preparation thereof |
| WO2023109802A1 (zh) * | 2021-12-14 | 2023-06-22 | 海思科医药集团股份有限公司 | 三环稠杂环类pde3/4双重抑制及其用途 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| EP4568677A1 (en) * | 2022-08-08 | 2025-06-18 | Verona Pharma PLC | Ensifentrine (rpl-554) for increasing trough lung function |
| EP4609864A4 (en) * | 2022-10-28 | 2026-02-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
| WO2025176871A1 (en) | 2024-02-23 | 2025-08-28 | Inke, S.A. | Process for preparing pyrimido[6,1-a]isoquinoline-4-ones |
| WO2025223528A1 (zh) * | 2024-04-27 | 2025-10-30 | 苏州君健一方生物医药有限公司 | 嘧啶并[6,1-a]异喹啉-4-酮衍生物 |
| WO2026003867A1 (en) * | 2024-06-24 | 2026-01-02 | Neuland Laboratories Limited | An improved process for the preparation of ensifentrine and its purification thereof |
| CN121226374A (zh) * | 2025-12-03 | 2025-12-30 | 长风药业股份有限公司 | 一种恩塞芬汀盐型化合物及其成盐方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW6284A1 (en) | 1983-05-05 | 1985-10-30 | Hoffmann La Roche | Novel pyrimidone derivatives |
| DE3816995A1 (de) | 1988-05-19 | 1989-11-23 | Hoechst Ag | Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen |
| CA2368413C (en) | 1999-03-31 | 2008-07-29 | Verona Pharma Plc | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
| JP5009799B2 (ja) * | 2004-09-08 | 2012-08-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の３−オキサ−１０−アザ−フェナントレン |
| AU2008316284A1 (en) | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Novel crystalline salts of montelukast |
| CA2796280A1 (en) | 2010-04-15 | 2011-10-20 | The Royal Institution For The Advancement Of Learning / Mcgill Universit Y | Topical treatments for pain |
| PT2603509E (pt) | 2010-08-09 | 2014-08-29 | Verona Pharma Plc | Forma cristalina de um composto pirimidio[6,1-a]isoquinolin-4-ona |
| EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| SI2968313T1 (en) | 2013-03-15 | 2018-05-31 | Verona Pharma Plc | Combination of medicines |
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| PT3332767T (pt) | 2014-09-15 | 2019-06-27 | Verona Pharma Plc | Formulação por inalação líquida compreendendo rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| WO2023076205A1 (en) | 2021-10-29 | 2023-05-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of ensifentrine and process for preparation thereof |
-
2015
- 2015-02-11 GB GB201502260A patent/GB201502260D0/en not_active Ceased
-
2016
- 2016-02-10 ES ES16704896T patent/ES3018557T3/es active Active
- 2016-02-10 WO PCT/GB2016/050313 patent/WO2016128742A1/en not_active Ceased
- 2016-02-10 CN CN202110415666.3A patent/CN113105453A/zh active Pending
- 2016-02-10 CN CN201680009645.9A patent/CN107406446B/zh active Active
- 2016-02-10 US US15/549,500 patent/US10463665B2/en active Active
- 2016-02-10 CA CA2974605A patent/CA2974605C/en active Active
- 2016-02-10 EP EP24189714.9A patent/EP4461358A3/en active Pending
- 2016-02-10 EP EP16704896.6A patent/EP3256472B1/en active Active
- 2016-02-10 JP JP2017541901A patent/JP7089366B2/ja active Active
- 2016-02-10 PT PT167048966T patent/PT3256472T/pt unknown
- 2016-02-10 MX MX2017010195A patent/MX382019B/es unknown
- 2016-02-10 AU AU2016217674A patent/AU2016217674B2/en active Active
-
2017
- 2017-07-20 IL IL253595A patent/IL253595B/en active IP Right Grant
- 2017-07-27 ZA ZA2017/05112A patent/ZA201705112B/en unknown
-
2019
- 2019-09-24 US US16/580,515 patent/US11491155B2/en active Active
-
2020
- 2020-07-15 AU AU2020205281A patent/AU2020205281B2/en active Active
- 2020-11-09 JP JP2020186284A patent/JP7110303B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3256472T (pt) | 2025-04-11 |
| US11491155B2 (en) | 2022-11-08 |
| CN107406446A (zh) | 2017-11-28 |
| CA2974605C (en) | 2024-02-13 |
| JP2018505192A (ja) | 2018-02-22 |
| NZ733926A (en) | 2023-10-27 |
| US10463665B2 (en) | 2019-11-05 |
| JP7110303B2 (ja) | 2022-08-01 |
| JP7089366B2 (ja) | 2022-06-22 |
| EP3256472B1 (en) | 2025-03-19 |
| US20180021337A1 (en) | 2018-01-25 |
| ZA201705112B (en) | 2022-05-25 |
| AU2016217674A1 (en) | 2017-08-10 |
| EP4461358A2 (en) | 2024-11-13 |
| CN107406446B (zh) | 2021-12-28 |
| US20200016158A1 (en) | 2020-01-16 |
| WO2016128742A1 (en) | 2016-08-18 |
| AU2020205281B2 (en) | 2021-07-15 |
| ES3018557T3 (es) | 2025-05-16 |
| CN113105453A (zh) | 2021-07-13 |
| MX2017010195A (es) | 2017-11-17 |
| GB201502260D0 (en) | 2015-04-01 |
| IL253595A0 (en) | 2017-09-28 |
| EP3256472A1 (en) | 2017-12-20 |
| IL253595B (en) | 2021-04-29 |
| JP2021046405A (ja) | 2021-03-25 |
| AU2020205281A1 (en) | 2020-08-06 |
| EP4461358A3 (en) | 2025-01-15 |
| CA2974605A1 (en) | 2016-08-18 |
| AU2016217674B2 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010195A (es) | Sal de un compuesto de pirimido [6,1-a]isoquinolin-4-ona. | |
| SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
| EA201792021A1 (ru) | Ингибитор jak | |
| MX368496B (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| EA201691353A1 (ru) | 5-фтор-4-имино-3-(алкил/замещенный алкил)-1-(арилсульфонил)-3,4-дигидропиримидин-2(1h)-он и способы их получения | |
| MX374439B (es) | Compuesto de piridona como inhibidor de c-met | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| WO2014192030A3 (en) | An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof | |
| MX2021012440A (es) | Farmacos precursores de oxabicicloheptanos. | |
| CY1124413T1 (el) | Ανταγωνιστες του υποδοχεα cgrp | |
| IN2014DN07996A (enExample) | ||
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| HUE053438T2 (hu) | [8-(fenilszulfonil)-3,8-diazabiciklo[3.2.1]okt-3-il](1h-1,2,3-triazol-4-il)metanonok | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| MX2019005504A (es) | Potenciadores de bmp. | |
| MX387349B (es) | Compuesto que inhibe la formación de complejo de c-myc/max/adn. | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| EA201791596A1 (ru) | Пиразоловые соединения | |
| UA40769S (uk) | Оформлення для передньої частини мультиварки |